Since pRCC cells reacted with elevated tumorigenicity and augmented PD-1/PD-L1 levels and ccRCC reacted with decreased tumorigenicity, further improvements in nivolumab-based therapy for renal carcinoma are needed. This evidence concerns the gene PDCD1 and renal carcinoma.